ClinicalTrials.gg
Active, not recruitingNCT06277960Updated May 30, 2025

Septal Ablation for Obstructive HCM

An interventional study of percutaneous intramyocardial septal radiofrequency ablation system in Hypertrophic Obstructive Cardiomyopathy (HOCM), sponsored by SuZhou Sinus Medical Technologies Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by SuZhou Sinus Medical Technologies Co.,Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Cardiomyopathy, Hypertrophic with a site in China — 31 open to participants now, 44 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
35th of 40
20 · median 83
Started
2024
with 9 others
No phase
20 of 72
12 open now
Primary completion
2025-12
later than 18 of 43 live
Registered
38th of 72
by date

Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 35th largest by enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2024, is one of 20 with no phase, reaches primary completion later than 18 of the 43 other live ones, and was the 38th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

31 of the 72 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

Hypertrophic cardiomyopathy (HCM) is a common clinical genetic-related disease, with a global incidence of 0.2%-0.5%, but only a few cases (10-20%) have been clinically diagnosed. About 70% of them are hypertrophic obstructive cardiomyopathy (HOCM), these HOCM patients have significant clinical symptoms, including progressively increasing fatigue, angina, exertional dyspnea, and syncope. Conservative medications are used to treat the vast majority of patients. Invasive therapy, which includes surgical myectomy, percutaneous transluminal septal myocardial ablation(PTSMA), percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) and percutaneous endocardial septal radiofrequency ablation (PESA) is introduced to patients with refractory symptoms or drug resistance. However, surgical operations are complicated and high risk procedures with high mortality. Interventional approaches are very difficult to perform and therefore the application is limited.

Previous researches have shown that interventricular septal radiofrequency ablation could effectively reduce the left ventricular outflow tract pressure gradient (LVOTG), thereby treating obstructive hypertrophic cardiomyopathy (HOCM). This device is based on the same radiofrequency ablation energy principle, however, the catheter is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum, which is potentially a lower risk route of access for septal ablation than currently attempted interventional approaches.

The purpose of this study is to evaluate the safety and efficacy of percutaneous intramyocardial septal ablation catheters in the treatment of obstructive hypertrophic cardiomyopathy.

03

Conditions studied

  • Hypertrophic Obstructive Cardiomyopathy (HOCM)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ age ≤ 75 years old, no gender limit.
  2. Subject has pressure gradient of left ventricular outflow tract (LVOT) ≥50 mmHg(with Systolic Anterior Motion)in the resting-state or after exercise stress test.
  3. Subject with (NYHA) cardiac function ≥ II grade.
  4. Subject with adequate drug treatment is not effective or cannot tolerate side effects of the drug.
  5. Subject was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed an ethics committee-approved form before conducting any special examinations and/or treatments related to the clinical study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or planned to conceive during a clinical study.
  2. Subject with interventricular septal thickness ≥ 30mm.
  3. Subject has undergone other ventricular septal volume reduction surgeries.
  4. Subject with complete right bundle branch block on .
  5. Subject with Sudden Cardiac Death Index ≥ 10%.
  6. Subject combined with other heart diseases requires surgical treatment.
  7. Subject with heart failure(Defined as resting heart failure after intensive anti-heart failure therapy, left ventricular fraction of ejecting\< 40%).
  8. Subject is mentally incapacitated or unable to understand the study requirements.
  9. Subject has participated in other clinical trials within 3 months.
  10. The investigator determines that there is any situation that affects the safety of the subjects or interferes with the evaluation of test results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    percutaneous intramyocardial septal radiofrequency ablation system

    Device: percutaneous intramyocardial septal radiofrequency ablation system

Interventions

  • Devicepercutaneous intramyocardial septal radiofrequency ablation system

    The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.

06

What researchers measure

Primary outcomes

  1. 30-day major adverse clinical events (MACE)

    30-day major adverse clinical events (MACE), including death, emergency surgery, severe pericardial effusion bleeding requiring pericardiocentesis or surgery, atrioventricular block, heart perforation, and surgery-related stroke.

    Time frame: 30-day

Secondary outcomes

  1. Technical success rate

    Technical success rate: the radiofrequency ablation catheter reaches the required treatment site, successfully completes the ablation, and is successfully withdrawn from the body.

    Time frame: 30-day

  2. Short Form 36 (SF-36) health survey questionnaire

    The life quality score of SF-36 would significantly improved after the procedure. The higher scores mean a better outcome.

    Time frame: 90-day

  3. Improvement of left ventricular outflow tract gradient (LVOTG)

    The improvement of LVOTG at post-procedure,30 days,3 months and 6 months after procedure. If the pressure gradient is reduced, the symptom will improve.

    Time frame: 6 months

  4. Improvement of NYHA functional classification

    The improvement of NYHA functional class at post-procedure,30 days,3 months and 6 months after procedure. The lower class mean a better outcome.

    Time frame: 6 months

  5. 6-min walk distance

    The increase of 6-min walk distance at post-procedure,30 days,3 months and 6 months after procedure.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 52 interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2024
First posted
Feb 26, 2024
StartActual
Mar 28, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 30, 2026
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277960
Lead sponsor
SuZhou Sinus Medical Technologies Co.,Ltd
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Mar 28, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion